GIPR and obesity disorder: The AP and NTS mediate satiation17,29 and emerging work has shone a light on the glucose-dependent insulinotropic polypeptide receptor (GIPR) as a therapeutic target for obesity with agonism of this receptor or activation of GIPR-expressing neurons suppressing food intake30,31.